Ketamine-Assisted Therapy Archives

2 minute read

UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center

November 15, 5:20 PM

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD).

AWKNF

2 minute read

Awakn’s Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion

By Lara Goldstein

April 28, 12:57 PM

The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.

AWKNF

2 minute read

Joint Venture Partnership Expands Access To Psychedelics Therapy For Some 50K Patients

By Lara Goldstein

April 12, 4:19 PM

Ketamine clinics operator Revitalist Lifestyle & Wellness Ltd. (OTCQB: RVLWF) and psilocybin bioscience and wellness platforms company Wake Network have partnered with GCM Partners LLC to offer new ketamine treatment locations in two facilities in Chicago, two in Orlando and one in Miami.

RVLWF

4 minute read

EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility

By Lara Goldstein

March 19, 9:01 AM

In light of the latest news regarding the DEA’s telehealth regulations and the

AWKNF

1 minute read

Awakn’s Ketamine Treatment For Alcohol Use Disorder Awarded UK’s Fast-Track Status

By Lara Goldstein

February 7, 12:10 PM

Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for its proprietary Ketamine-Assisted Therapy (KAT) to treat severe AUD.

AWKNF